These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28371136)

  • 1. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
    Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats.
    Turkseven S; Bolognesi M; Brocca A; Pesce P; Angeli P; Di Pascoli M
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G298-G304. PubMed ID: 31813234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
    Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
    World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
    Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
    Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
    J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
    Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
    J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    Cerini F; Vilaseca M; Lafoz E; García-Irigoyen O; García-Calderó H; Tripathi DM; Avila M; Reverter JC; Bosch J; Gracia-Sancho J; García-Pagán JC
    J Hepatol; 2016 Apr; 64(4):834-42. PubMed ID: 26686269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
    Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
    J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
    J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.
    Marrone G; Maeso-Díaz R; García-Cardena G; Abraldes JG; García-Pagán JC; Bosch J; Gracia-Sancho J
    Gut; 2015 Sep; 64(9):1434-43. PubMed ID: 25500203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.
    Lee KC; Hsu WF; Hsieh YC; Chan CC; Yang YY; Huang YH; Hou MC; Lin HC
    Dig Dis Sci; 2019 Jan; 64(1):102-112. PubMed ID: 30288660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
    Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension.
    Jalan R; De Chiara F; Balasubramaniyan V; Andreola F; Khetan V; Malago M; Pinzani M; Mookerjee RP; Rombouts K
    J Hepatol; 2016 Apr; 64(4):823-33. PubMed ID: 26654994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icaritin induces cell death in activated hepatic stellate cells through mitochondrial activated apoptosis and ameliorates the development of liver fibrosis in rats.
    Li J; Liu P; Zhang R; Cao L; Qian H; Liao J; Xu W; Wu M; Yin Z
    J Ethnopharmacol; 2011 Sep; 137(1):714-23. PubMed ID: 21726622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
    Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
    Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
    Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
    FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats.
    Klein S; Frohn F; Magdaleno F; Reker-Smit C; Schierwagen R; Schierwagen I; Uschner FE; van Dijk F; Fürst DO; Djudjaj S; Boor P; Poelstra K; Beljaars L; Trebicka J
    Sci Rep; 2019 Feb; 9(1):2256. PubMed ID: 30783172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.